Toggle navigation
Home
Sitemap
日本語
Search
About Astellas
Contact Us
Search
Only Astellas completed Studies will be displayed.
Please select values from or type values into dropdown menus below, and click Search button to proceed.
To view all studies, leave all values blank and click Search.
Therapeutic Area:
Cardiovascular
Central Nervous System
Diabetes
Gastrointestinal
Infectious Diseases
Inflammation and Immunology
Muscular Diseases
Nephrology
Oncology
Ophthalmology
Pain
Transplantation
Urology
Medical Indication or Disease:
Acute myeloid leukemia
Adrenocortical carcinoma
Age-Related Macular Degeneration
Aggressive schizophrenia
Alzheimer's disease
Anemia with chronic kidney disease
Antineoplastic drug-induced nausea and vomiting
Benign prostatic hyperplasia
Bipolar depression
Bladder pain
Brain tumor
Chronic constipation
Chronic kidney disease
Clostridium difficile infection
Deep mycosis
Dementia
Diabetic kidney disease
Diabetic macular edema
Endometriosis
Fibromyalgia
Functional dyspepsia
Hepatocellular carcinoma
Herpes zoster
Hyperphosphatemia
Hypertensive emergency
Hyperuricemia
Insomnia
Invasive fungal infection
Irritable bowel syndrome
Lower urinary tract syndrome / Benign prostatic hyperplasia
Lupus nephritis
Major depressive disorder
Muscle fatigue
Myasthenia gravis
Myocardial perfusion imaging
Nephrotic syndrome
Neurogenic detrusor overactivity
Non-small cell lung cancer
Osteoarthritis
Ovarian cancer
Overactive bladder
Painful diabetic neuropathy
Pancreatic cancer
Peripheral neuropathic pain
Peripheral neuropathy
Pollinosis
Prevention of CMV infection
Prevention of rejection after organ transplant
Prostate cancer
Psoriasis
Relapsed or refractory malignant lymphoma (white blood cell cancer)
Renal cell carcinoma
Restless leg syndrome
Rheumatoid arthritis
Schizophrenia
Solid tumors
Stargardt’s Macular Dystrophy (SMD)
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Ulcerative colitis
Urothelial carcinoma
Vernal keratoconjunctivitis
Compound Name:
AGS-16C3F
AGS67E
ASP0113
ASP015K / peficitinib hydrobromide
ASP0456 / linaclotide
ASP0777
ASP0819
ASP1517 / roxadustat
ASP1585 / bixalomer
ASP1707
ASP1941 / ipragliflozin
ASP2151 / amenamevir
ASP2215 / gilteritinib fumarate
ASP3318 / reldesemtiv
ASP3325
ASP3550 / degarelix acetate
ASP3652
ASP3662
ASP4070
ASP4132
ASP4901
ASP5094
ASP5878
ASP6294
ASP6981
ASP7015 / leuprorelin acetate
ASP7316 / MA09-hRPE cells
ASP7465 (ASG-22CE) / enfortumab vedotin
ASP7487 / OSI-906 / linsitinib
ASP7962
ASP7991
ASP8062
ASP8232
ASP8273 / naquotinib mesilate
ASP8477
ASP8825 / gabapentin enacarbil
ASP9853
ATG-F / anti-T-lymphocyte immune globulin
AY4166 / nateglinide
BAL8557 / isavuconazonium sulfate
CDP870 / certolizumab pegol
CVT3146 / regadenoson
EB178 / mirabegron + solifenacin succinate
EC905 / solifenacin + tamsulosin
FK199 / zolpidem tartrate
FK463 / micafungin
FK506 / tacrolimus
FK506E / tacrolimus extended-release
FK949 / quetiapine fumarate
Lodopin / zotepine
MDV3100 / enzalutamide
NGX-4010 (ASP0805) / capsaicin
OPT-80 / fidaxomicin
OSI-774 / erlotinib
TMX-67 / febuxostat
YC-93 / nicardipine hydrochloride
YM060 / ramosetron hydrochloride
YM178 / mirabegron
YM443 / acotiamide hydrochloride hydrate
YM617 / tamsulosin HCl
YM905 / solifenacin succinate
Study ID:
Format: XXXX-CL-XXXX
USEFUL LINKS
ClinicalTrials.gov
ClinicalTrialsRegister.eu
ClinicalTrials.jp
European Federation of Pharmaceutical Industries and Associations
European Public Assessment Report (for Drug products approved by EMA)
FDA Approved Drug Products
FDA PostMarket Drug Safety Information for Patients and Providers (for Drug products approved by EMA)
PhRMA